Danziten(TM)

Finally, a Nilotinib With No Mealtime Restrictions1,a

a

Patients should not consume grapefruit products and other foods that are known to inhibit CYP3A4 at any time during DanzitenTM treatment.

Danziten(TM): Finally, a Nilotinib With No Mealtime Restrictions

Hello {{Contact.FirstName}} {{Contact.LastName}},

DanzitenTM: Proven Efficacy of Tasigna®, but With No Fasting Requirements1,a
Learn more about DanzitenTM

DanzitenTM has bioequivalence to Tasigna® with improved bioavailability allowing for a lower dose, and consistent pharmacokinetics1-3

DanzitenTM is a kinase inhibitor indicated for the treatment of1:

Adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.

Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib.

WARNING: QT PROLONGATION and SUDDEN DEATHS

See Full Prescribing Information for complete Boxed Warning.

  • Nilotinib prolongs the QT interval. Prior to DANZITEN administration and periodically, monitor for hypokalemia or hypomagnesemia and correct deficiencies. (5.3) Obtain ECGs to monitor the QTc at baseline, seven days after initiation, and periodically thereafter, and following any dose adjustments. (5.3, 5.4, 5.8, 5.12)

  • Sudden deaths have been reported in patients receiving nilotinib. (5.4) Do not administer DANZITEN to patients with hypokalemia, hypomagnesemia, or long QT syndrome. (4, 5.3)

  • Avoid use of concomitant drugs known to prolong the QT interval and strong CYP3A4 inhibitors. (7.1, 7.2)

Dosage Equivalence and Administration Instructions1,4
Approved Indications DanzitenTM Dosage and Administration Tasigna® Dosage and Administration
Adult patients with newly diagnosed Ph+ CML-CP 142 mg orally twice daily
at ~12-hour intervals with or without fooda		 300 mg orally twice daily on an empty stomach

No food should be consumed for ≥2 hours before the dose is taken and for ≥1 hour after the dose is taken
Adult patients with resistant or intolerant Ph+ CML-CP and CML-AP 190 mg orally twice daily
at ~12-hour intervals with or without fooda 		400 mg orally twice daily on an empty stomach

No food should be consumed for ≥2 hours before the dose is taken and for ≥1 hour after the dose is taken

This chart is offered as a side-by-side comparison based on the product labels. Azurity does not confirm other products' labels. Reporting of any adverse effects, product quality complaints, or medical information request regarding CML-CP and CML-AP treatment options should be directed to their respective manufacturer.

DanzitenTM may not be substitutable with other nilotinib products on a milligram per milligram basis; to avoid medication errors, including overdosage or underdosage, when using DanzitenTM ensure that the recommended dosage of DanzitenTM (not the recommended dosage of other nilotinib products) is prescribed.1

How DanzitenTM Is Supplied1

DanzitenTM is available as 71 mg and 95 mg tablets.

DanzitenTM is supplied in a blister pack that assists patients in monitoring their medication doses effectively.

Additional Dosing Information1

DanzitenTM may be given in combination with hematopoietic growth factors, such as erythropoietin or replaced with Granulocyte colony-stimulating factor (G-CSF) if clinically indicated. DanzitenTM may be given with hydroxyurea or anagrelide if clinically indicated.

Reduce starting dose of DanzitenTM in patients with hepatic impairment.

Withhold or reduce DanzitenTM dosage for hematological toxicities (neutropenia, thrombocytopenia) that are not related to underlying leukemia.

For non-hematologic laboratory abnormalities (Grade ≥3) such as elevated serum lipase, amylase, bilirubin, or hepatic transaminases, withhold DanzitenTM and monitor levels, resume treatment at 190 mg once daily when serum levels return to Grade ≤1.

Advise patients to swallow the tablets whole with water and not to cut, crush, or chew the tablets.

Advise patients to take DanzitenTM with or without food. Patients should not consume grapefruit products and other foods that are known to inhibit CYP3A4 at any time during DanzitenTM treatment.

If the patient missed a dose of DanzitenTM, the patient should take the next scheduled dose at its regular time. The patient should not take 2 doses at the same time.

IMPORTANT SAFETY INFORMATION

DANZITENTM (nilotinib) tablets, for oral use

DANZITEN is a kinase inhibitor indicated for the treatment of:

  • Adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
  • Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib.

WARNING: QT PROLONGATION and SUDDEN DEATHS

See Full Prescribing Information for complete Boxed Warning.

  • Nilotinib prolongs the QT interval. Prior to DANZITEN administration and periodically, monitor for hypokalemia or hypomagnesemia and correct deficiencies. (5.3) Obtain ECGs to monitor the QTc at baseline, seven days after initiation, and periodically thereafter, and following any dose adjustments. (5.3, 5.4, 5.8, 5.12)

  • Sudden deaths have been reported in patients receiving nilotinib. (5.4) Do not administer DANZITEN to patients with hypokalemia, hypomagnesemia, or long QT syndrome. (4, 5.3)

  • Avoid use of concomitant drugs known to prolong the QT interval and strong CYP3A4 inhibitors. (7.1, 7.2)

ADDITIONAL IMPORTANT SAFETY INFORMATION

Contraindications

DANZITEN is contraindicated in patients with hypokalemia, hypomagnesemia, or long QT syndrome.

Warnings and Precautions

Substitution With Other Nilotinib Products and Risk of Medication Errors: DANZITEN tablets may not be substitutable with other nilotinib products, including other nilotinib tablets, on a milligram per milligram basis. Confirm that the intended nilotinib product is being prescribed and dispensed.

Myelosuppression: Monitor complete blood count (CBC) during therapy and manage by treatment interruption or dose reduction.

Cardiac and Arterial Vascular Occlusive Events: Evaluate cardiovascular status, monitor and manage cardiovascular risk factors during DANZITEN therapy.

Pancreatitis and Elevated Serum Lipase: Monitor serum lipase; if elevations are accompanied by abdominal symptoms, interrupt doses and consider appropriate diagnostics to exclude pancreatitis.

Hepatotoxicity: Monitor hepatic function tests monthly or as clinically indicated.

Electrolyte Abnormalities: DANZITEN can cause hypophosphatemia, hypokalemia, hyperkalemia, hypocalcemia, and hyponatremia. Correct electrolyte abnormalities prior to initiating DANZITEN and monitor periodically during therapy.

Tumor Lysis Syndrome: Maintain adequate hydration and correct uric acid levels prior to initiating therapy with DANZITEN.

Hemorrhage: Hemorrhage from any site may occur. Advise patients to report signs and symptoms of bleeding and medically manage as needed.

Fluid Retention: Monitor patients for unexpected rapid weight gain, swelling, and shortness of breath. Manage medically.

Effects on Growth and Development in Pediatric Patients: Growth retardation has been reported in pediatric patients treated with nilotinib. Monitor growth and development in pediatric patients.

Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of potential risk to a fetus and to use effective contraception.

Treatment Discontinuation: Patients must have typical BCR-ABL transcripts. An FDA-authorized test with a detection limit below MR4.5 must be used to determine eligibility for discontinuation. Patients must be frequently monitored by the FDA authorized test to detect possible loss of remission.

Adverse Reactions

The most commonly reported non-hematologic adverse reactions (≥20%) in adult patients are nausea, rash, headache, fatigue, pruritus, vomiting, diarrhea, cough, constipation, arthralgia, nasopharyngitis, pyrexia, and night sweats. Hematologic adverse drug reactions include myelosuppression: thrombocytopenia, neutropenia, and anemia.

These are not all the possible side effects of DANZITEN. Please see Full Prescribing Information for a full list.

Drug Interactions

Strong CYP3A Inhibitors: Avoid concomitant use, including grapefruit juice with DANZITEN or reduce DANZITEN dose if concomitant use cannot be avoided.

Strong CYP3A Inducers: Avoid concomitant use with DANZITEN.

Proton Pump Inhibitors: Use short-acting antacids or H2 blockers as an alternative to proton pump inhibitors.

See Full Prescribing Information for Specific Drugs and Interactions.

Use in Specific Populations

Lactation: Advise women not to breastfeed.

Pediatric Use: The safety and effectiveness of nilotinib in pediatric patients below the age of 1 year with newly diagnosed, or who are resistant to or intolerant to Ph+ CML in chronic phase and accelerated phase have not been established.

The Important Safety Information does not include all the information needed to use DANZITEN safely and effectively. Please see Full Prescribing Information for DANZITEN.

To Report SUSPECTED ADVERSE REACTIONS, contact Azurity Pharmaceuticals, Inc. at 1-800-461-7449, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.

References: 1. DANZITEN [prescribing information]: Woburn, MA: Azurity Pharmaceuticals, Inc; 2024. 2. Radich J, Mauro M, Jain P, et al. Population pharmacokinetic (PopPK) modeling for a novel nilotinib formulation. Presented at: SOHO 2024 Annual World; September 4-7, 2024; Houston, TX. 3. Data on file. Azurity Pharmaceuticals. 2024. 4. Tasigna (prescribing information): East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2024.

Warm Regards,

{{User.Name}}
{{User.Title}}Cell: {{User.MobilePhone}}
Email: {{User.Email}}

Azurity

Azurity Pharmaceuticals, Inc. | 8 Cabot Road, Suite 2000, Woburn, MA 01801

The information contained herein, including product information, is intended only for healthcare providers in the United States.

© 2025 Azurity Pharmaceuticals, Inc. All Rights Reserved. Danziten™ is a trademark of Azurity Pharmaceuticals, Inc.

All trademarks referred to are the property of their respective owners. PP-DAN-US-0104

Tasigna® is a registered trademark of Novartis Pharmaceuticals Corporation.

UNSUBSCRIBE PRIVACY CONTACT US